All News

Urology Times 2006 Media Kit

A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.

Former New York Knicks basketball star Earl "The Pearl" Monroe is the point man for the "Flomax One-Week Challenge," a national campaign to educate men about BPH.

The National Cancer Institute and the National Human Genome Research Institute have launched a comprehensive effort to accelerate the understanding of the molecular basis of cancer through genome analysis technologies, especially large-scale genome sequencing.

Researchers at the University of California, San Francisco have discovered that the activity of several embryonic stem cell genes is elevated in testicular cancer, providing some of the first molecular evidence of a link between embryonic stem cells and cancer.

A third interim safety analysis of an ongoing multicenter phase II trial of NX-1207, for the treatment of BPH, has revealed no serious side effects, according to Nymox Pharmaceutical Corp., the drug's manufacturer.

Urology Associates of Nashville, TN has opened a clinic dedicated to women's sexual health.

Measurement of telomerase activity in urine appears promising for the detection of bladder cancer in men, according to a study published last week in JAMA.

New Orleans--Hurricane Katrina has come and gone and in its wake we are left with devastation, carnage, and sadness. The region has more than 6,000 displaced physicians, and 156 AUA members have practices in the affected areas, according to AUA.

Mayo Clinic researchers say they have discovered that a molecule known as B7-H1 may serve as a "molecular armor," protecting kidney cancer by allowing it to grow and spread.

Extended-release tolterodinetartate (Detrol LA) significantly improves lower urinary tract storage symptoms from baseline in men after unsuccessful treatment with alpha-blocker therapy, according to a study published in the current Journal of Urology (2005; 174:2273-5).

An herbal extract preparation known as Zyflamend appears to suppress the growth of prostate cancer cells and induces the cells to self-destruct, according to Columbia University researchers.

Boehringer Ingelheim and the FDA have notified health care professionals of revisions to the precautions and adverse reactions sections of the prescribing information for tamsulosin hydrochloride (Flomax) for the treatment of BPH.

Men with infertility and abnormal sperm counts have a 20-fold greater incidence of testicular cancer than men in the general population, according to a study published in the Journal of Urology (2005; 174:1819-22).

Dendreon Corp. has reached an agreement with the FDA under the Special Protocol Assessment procedure to amend the design of its ongoing phase III (D9902B) clinical trial of sipuleucel-T (Provenge), the company?s investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Smaller ambulatory surgery centers continue to report better net incomes per case than their larger counterparts, while larger ASCs report lower operating costs, according to a newly released report from the Medical Group Management Association.

Washington--Counterfeit prescription drugs pose a "potentially serious health threat" in the United States, one that can result in serious or deadly consequences for patients because of unscrupulous acts of profiteers who take advantage of a lack of uniform regulation and enforcement.

Nerve stim device provides office-based OAB treatment

Business interruption insurance compensates you for lost income if you have to vacate the premises due to disaster-related damage.

As the only nonprofit organization dedicated to teaching urology in developing countries, International Volunteers in Urology (IVU) provides a number of opportunities for residents and practicing urologists alike. Volunteers offer their teaching and clinical skills and learn about resourcefulness and compassion in return, IVU President Catherine deVries, MD, says in this exclusive interview. She was interviewed by UT Editorial Consultant Richard D. Williams, MD, professor and chairman of the department of urology at the University of Iowa, Iowa City. Dr. Williams also leads a volunteer surgical team that travels to Haiti each year.

Patients need to understand that, based on their age, prevalence of prostate cancer can be predicted.

St. Louis--In the opinion of many, the work emanating from Scott Hultgren, PhD's laboratory in the molecular microbiology and microbial pathogenesis program at Washington University School of Medicine will revolutionize the treatment of urinary tract infections, a particularly vexing clinical challenge.

Rochester, MN--Gleason scores are not what they used to be. Low-grade cancers, as described by Gleason scores 2 to 5, have virtually disappeared, while higher-grade cancers, particularly those identified as Gleason 6, have surged upward, according to a study performed at the Mayo Clinic, Rochester, MN.

Farmington, CT--Before epidemiologists and urologists pat themselves on the back for the improvements seen in outcomes following definitive treatment for prostate cancer, they may want to consider data assimilated by Peter C. Albertsen, MD, professor and chief of the division of urology, University of Connecticut Health Center, Farmington.

Montreal--Putting to rest a long-standing debate about the number of elements that the external anal sphincter (EAS) contains, magnetic resonance imaging and three-dimensional modeling here at the annual meeting of the International Continence Socity shows the EAS has three components, according to researchers from the University of Michigan, Ann Arbor.

Montreal--While long-term studies on vaginal meshes used in pelvic organ prolapse surgery are lacking, several meshes are being studied in experimental settings and are being found effective and safe at providing anatomical correction.

Montreal--Botulinum toxin type B appears to be efficacious for the treatment of overactive bladder, although the agent has a short duration of action, according to British researchers. While their small, randomized, double-blind, placebo-controlled, crossover-design study specifically examined serotype B, the researchers said botulinum toxin A is likely the preferred agent because of its greater durability.

Montreal--Two newer-generation antimuscarinic agents—solifenacin succinate (VESIcare) and extended-release tolterodine tartrate (Detrol LA)—improve symptoms of overactive bladder, but solifenacin appears to provide superior outcomes, according to a trial conducted in collaboration with the manufacturer of solifenacin. Benefits of solifenacin appear to be due, at least in part, to the availability of two approved doses of the drug, researchers say.